RSPO3 and neoplasm: Although these were not sensitive to anti-RSPO3 treatment only, the combination of anti-RSPO3 with paclitaxel synergistically reduced tumor growth in most cases, being accompanied by reduced nuclear β-catenin, proliferation and CSC frequency against enhanced differentiation [152].